Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Portfolio Pulse from Vandana Singh
A British study shows that COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer, and Moderna significantly reduce the incidence of arterial thromboses, which cause heart attacks and strokes. Despite some rare adverse effects, the findings support the continued use of these vaccines.
August 13, 2024 | 6:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech/Pfizer's COVID-19 vaccine reduces arterial thromboses but has rare side effects like myocarditis. Pfizer raised its 2024 guidance.
The study's positive findings on reducing arterial thromboses and Pfizer's raised 2024 guidance suggest a positive short-term impact on BioNTech's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Pfizer's COVID-19 vaccine reduces arterial thromboses but has rare side effects like myocarditis. Pfizer raised its 2024 guidance.
The study's positive findings on reducing arterial thromboses and Pfizer's raised 2024 guidance suggest a positive short-term impact on Pfizer's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
AstraZeneca's COVID-19 vaccine reduces arterial thromboses but has rare side effects. The company has ceased its vaccine due to updated alternatives.
The study highlights both the benefits and rare side effects of AstraZeneca's vaccine. However, the company's cessation of its vaccine due to updated alternatives may neutralize the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Moderna's COVID-19 vaccine reduces arterial thromboses but has rare side effects like myocarditis. The company lowered its 2024 sales guidance.
While the study shows benefits in reducing arterial thromboses, Moderna's lowered 2024 sales guidance due to weaker demand may negatively impact its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90